Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • Risankizumab - Crohn Disease
    Clinical Study Number 1311.6
    Study Indication Crohn Disease
    Product Risankizumab
    Generic Name Risankizumab
    Lab Code BI 655066
    Clinical Phase II
    Study Title

    A Phase 2, Multicenter, Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease Who Are Naïve to or Were Previously Treated With Anti-TNF Therapy

    Study Document
    Trial synopsis 1311.6 English